FDA To Pilot "Real-Time" Meetings For 510(k) Supplement Reviews
This article was originally published in The Gray Sheet
Manufacturers will have the option to engage FDA in "real-time" meetings to discuss resubmitted 510(k) supplement applications under a pilot scheduled to commence in the next two weeks, FDA staffers say.
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.